Technology advances enable contract service providers to keep pace with the demands of existing and emerging biologic-based therapies.
Technology advances enable contract service providers to keep pace with the demands of existing and emerging biologic-based therapies.
The panelists in this roundtable discussion included: John Allinson, head of biomarker strategy, drug development services at LGC; Martha S. Rook, head of novel therapies, process solutions, MilliporeSigma; Joe Codamo, general manager, Patheon; Brian Hampson, Vice-President, Global Manufacturing Sciences and Technology, PCT, a Caladrius Company; Stephen Gacheru, Executive Director–Biopharmaceutical Product Development, PPD Laboratories; Bruce Stauffer, Executive Director–Immunochemistry Department, PPD Laboratories; and Mark Rogers, VP USA–Life Science, SGS.
Download the
BioPharm International 2016 Outsourcing Resources eBook.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.